Clinical trial advertising is any recruitment material, print, digital, or broadcast, used to identify and enroll prospective study subjects. It's regulated at three separate layers before a single ad runs: an Institutional Review Board (IRB), Food and Drug Administration (FDA) guidance, and the ad platform's own healthcare policy, whether that's Google Ads or Meta.
Recruitment advertising is treated as the start of the informed consent process, not a separate marketing activity that gets reviewed after a complaint. An IRB has to approve an ad before a single prospective subject ever sees it. Google and Meta then apply their own healthcare ad policies on top of that IRB approval, and the two reviews don't always agree on the same wording. That three-layer stack, not one review alone, is what a recruitment ad has to clear before it runs.
What IRB review of recruitment materials requires
An IRB must review and approve every piece of recruitment material before it is used, because both the Office for Human Research Protections (OHRP) and the FDA treat recruitment as the start of informed consent, not a separate marketing step. OHRP administers the HHS Common Rule under 45 CFR Part 46, the baseline framework recruitment-material review sits inside. That review covers more than print ads: flyers, broadcast spots, social media posts, email and SMS scripts, phone scripts, website copy, and patient-portal listings all count as recruitment material and all require sign-off before use, with one narrow FDA carve-out for bare trial listings limited to basic study facts such as title, purpose, eligibility summary, site location, and contact information. Digital and social recruitment doesn't get a lighter touch either; Advarra's guidance on social media recruitment confirms it requires the same IRB review as traditional print and broadcast ads.
The approval criteria come from two overlapping regulations. Under 45 CFR 46.111, an IRB can only approve research where risks are minimized, risk is reasonable relative to expected benefit, and additional safeguards are in place for subjects vulnerable to coercion or undue influence. The parallel FDA regulation, 21 CFR 56.109, gives IRBs the authority to approve, require modification of, or disapprove all covered research activities, the authority FDA's recruitment guidance applies to ad materials, and it requires that informed-consent information meets the content standard in 21 CFR Part 50.
That vulnerable-population and undue-influence standard is the reason recruitment ads get scrutinized so closely. FDA calls ad review especially critical when a study may involve subjects likely to be vulnerable to undue influence, and framing that leans on payment as the reason to participate is exactly the kind of influence reviewers screen for. Approval isn't a one-time event either. Changing a previously approved ad's wording, swapping an image, or even resizing a disclosure font requires a new IRB pass before the updated version runs.
FDA's position on recruitment advertising: what counts as the start of subject selection
FDA does not object to direct advertising for study subjects, but it considers the advertising itself the start of the informed consent and subject selection process, which is why an IRB reviews the ad against the same consent document and protocol the study runs on. That position comes from the FDA's Recruiting Study Subjects information sheet, which expects IRBs to assure that advertising is not unduly coercive and does not promise a certainty of cure beyond what is outlined in the consent document and the protocol.
That standard applies regardless of channel. A recruitment ad running in print, broadcast, digital display, or a social feed is held to the same coercion and certainty-of-cure standard; the medium doesn't change the rule. A separate piece of FDA guidance, Payment and Reimbursement to Research Subjects, governs the money itself: payment to subjects is a recruitment incentive rather than a benefit, and the IRB reviews the amount, method, and timing of payment to confirm none of it is coercive or presents undue influence.
This reading isn't unique to FDA's own information sheet. WIRB-Copernicus Group guidance confirms the same standard: recruitment materials are the start of the informed-consent process, and neither OHRP nor FDA maintains a standalone recruitment regulation separate from the informed-consent framework itself.
What ad elements are allowed and prohibited
Two failure patterns account for most recruitment ads an IRB kicks back: certainty-of-cure language and payment used as the hook. Both read as undue influence regardless of how the rest of the ad is written, and University of Utah IRB guidance translates both into a concrete list of prohibited ad practices.
Allowed, stated plainly:
- The condition under study, described in lay language
- A clear statement that the study is investigational, not an approved treatment
- Basic eligibility criteria, such as age, diagnosis, or prior treatment history
- The study location and phase
- A factual, unemphasized mention that compensation for time and travel may be available
- Contact information for the study team
Prohibited, and the rule each one violates:
- "Free medical treatment" promises when the intent is only that subjects will not be charged for taking part, a mischaracterization FDA's recruitment guidance bars by name
- Claims of a favorable outcome beyond what the consent document and protocol state
- "New treatment" language that omits investigational status, misleading a reader about what they are agreeing to
- Payment or the amount to be paid emphasized through larger or bold type or other visual prominence; University of Utah IRB guidance adds that even a plainly stated dollar figure can be ruled coercive or unduly influential
- Exculpatory or coercive language that reads as a waiver of a subject's rights
- For drug or device studies, any claim inconsistent with existing FDA labeling
Platform ad policies for clinical trial recruitment
IRB approval and platform approval are two separate gates, and an ad cleared by one can still be rejected by the other. Google and Meta each maintain their own healthcare ad policies, and neither treats IRB sign-off as sufficient on its own.
Under Google's clinical trial recruitment policy, recruitment ads are permitted only in a defined list of countries that includes the US. Even where they're allowed, the ads can't promote a prescription drug, can't create misleading expectations about the product being tested, and can't imply the product being tested is already known to be safe. A separate certification track, Google's healthcare and medicines policy, covers pharmaceutical manufacturer and health insurance advertisers and sits alongside the clinical-trial-specific rule as its own approval step.
Meta's restriction works differently. Under its personal attributes policy, an ad can't directly address a viewer's health condition, so copy can't ask "do you have diabetes?" It has to frame around the offer or service instead, something closer to "an investigational diabetes treatment study is enrolling." Meta's health and wellness policy layers a second gate on top of that, restricting exploitative framing and age-gating certain health verticals.
The practical consequence is that a sponsor needs sign-off from the IRB first, then has to separately satisfy each platform's healthcare ad-review policy, and the two reviews don't always land on the same wording.
Approved channels in practice
Paid search, paid social, sponsor and site websites and patient portals, and community or print placements built through patient advocacy partners are the channels that most consistently satisfy IRB approval, FDA's informed-consent standard, and platform ad policy at the same time. Each format has simply adapted to work within those three constraints.
Paid search and paid social carry the tightest geo-targeting, letting a sponsor limit an ad's reach to the metro areas around a trial site, which matters given how far behind pace most trial enrollment timelines run. Sponsor and site websites, along with patient portals, carry more space for eligibility detail and IRB-approved consent language than a 30-second video or a single feed ad can fit. Community and print placements built through patient advocacy partners reach populations who may not respond to a paid digital ad at all, particularly in oncology and rare-disease studies where the eligible population is small.
Sponsors weighing whether to run this in-house often look at how paid-media specialists compare on pricing and vertical fit before committing to a channel mix, since every channel choice inherits the IRB and platform review timelines these rules create.
Annotated examples of compliant clinical trial recruitment ads
The three examples below are illustrative, composite recruitment ads annotated against the IRB, FDA, and platform rules covered in this article. None represents a real sponsor, agency, drug, or trial; each is built to show how the allowed and prohibited language above translates into an actual ad.
Example 1: a geo-targeted Google Search ad for a Type 2 diabetes study. The ad triggers on searches related to diabetes management, targets a defined radius around a hypothetical study site, names the condition in plain language, and states plainly that the study is investigational. It mentions that compensation for time and travel may be available without featuring a dollar figure in the headline, lists the study's location and phase, and closes with "see if you qualify" instead of a cure claim.
What makes it compliant: it uses "investigational" rather than implying an approved treatment, it keeps compensation factual and unemphasized rather than headline bait, and it avoids implying the tested product is already known to be safe, the specific failure Google's clinical trial recruitment policy flags.
Example 2: a Meta feed ad for a chronic migraine prevention study. Instead of asking a personal-attribute question like "do you get migraines?", the copy is framed around the offer itself: "an investigational migraine prevention study is enrolling near [city]." It links to an IRB-approved eligibility screener rather than collecting health information in the ad, and it includes no before-and-after imagery or outcome claim of any kind.
What makes it compliant: framing around the offer instead of a personal health attribute satisfies Meta's personal attributes policy directly, and the absence of outcome claims or imagery avoids the certainty-of-cure problem that trips up ads for chronic conditions specifically.
Example 3: a patient-portal or community print listing for an oncology trial. The listing names the trial phase and a generic sponsor category, an academic research center rather than a real company, and uses "evaluating an investigational therapy" instead of "new cure." It discloses compensation only in a footnote rather than the body copy, and it closes with the IRB approval statement many institutions require in ad footers.
What makes it compliant: the investigational-therapy language avoids the "new treatment" mischaracterization Utah IRB guidance flags, the footnote-only compensation disclosure keeps payment unemphasized, and the IRB approval statement gives a reader the same institutional review signal the ad itself had to clear.
Frequently asked questions about clinical trial advertising
These four questions cover the parts of clinical trial advertising rules that sponsor, CRO, and site marketers ask about most often, from IRB approval to platform-specific restrictions on Google and Meta.
What is clinical trial advertising?
Clinical trial advertising is any recruitment material, print, digital, or broadcast, used to identify and enroll prospective study subjects. It is regulated as the start of the informed consent process, not as ordinary marketing, and has to clear IRB review before it runs.
Does an IRB have to approve every clinical trial recruitment ad?
Yes, with one narrow exception. Recruitment materials, including social posts, phone scripts, and website copy, require IRB approval before use under 21 CFR 56.109 and 45 CFR 46.111. FDA exempts only bare trial listings limited to basic study facts, and any change to approved wording or images needs a new pass.
Can you advertise clinical trial recruitment on Google and Meta?
Yes, but each platform layers its own healthcare ad policy on top of IRB approval. Google restricts clinical trial recruitment ads to a defined list of countries and prohibits misleading safety claims, while Meta prohibits directly addressing a personal health attribute in the ad copy.
Can a clinical trial ad mention payment for participation?
Yes, factually. FDA's recruiting guidance allows an ad to state that subjects will be paid, but bars emphasizing the payment or the amount through means like larger or bold type. Some IRBs, including the University of Utah's, can also rule a stated dollar figure unduly influential.
What it takes to get a recruitment ad approved
Every clinical trial recruitment ad has to clear the same three-layer stack before it runs: IRB approval, FDA's informed-consent standard, and the ad platform's own healthcare policy. None of the three substitutes for the other two, and a sponsor's legal team, IRB liaison, and media buyer typically all touch the same ad before it goes live. For a sponsor or site deciding whether that process stays in-house or moves outside, the next practical step is figuring out which specialist agencies run compliant patient-recruitment campaigns.